Following the success of our 2019 reading list (available here) we’ve decided to put together a list of 25 publications to celebrate the cancer prevention group’s achievements in what has been a very strange and unpredictable year! As with last year, the names in bold are authors from our group.
Happy reading!
| Paper name | Objective | Journal, Authors |
| 1. Management strategies for the colonoscopic surveillance of people with Lynch syndrome during the COVID-19 pandemic. | Proposal for the use of faecal immunochemical test (FIT) as a method of risk stratification of individuals with Lynch syndrome who are due surveillance colonoscopy. | Gut
Kevin J Monahan, Anne Lincoln, James E East…. Huw J W Thomas & Peter Sasieni. |
| 2. A case-control study to evaluate the impact of the breast screening programme on mortality in England | Over the past 30 years since the implementation of the National Health Service Breast Screening Programme, improvements in diagnostic techniques and treatments have led to the need for an up-to-date evaluation of its benefit on risk of death from breast cancer. | British Journal of Cancer
Roberta Maroni, Nathalie J. Massat, Dharmishta Parmar, Amanda Dibden, Jack Cuzick, Peter D. Sasieni & Stephen W. Duffy |
| 3. Introducing HPV primary testing in the age of HPV vaccination: Projected impact on colposcopy services in Wales | The aim of this study was to determine the demand for colposcopy in Cervical Screening Wales programme after the introduction of human papillomavirus (HPV) cervical screening, which coincided with the start of screening of women vaccinated against HPV 16/18. | British Journal of Obstetrics and Gynaecology
Francesca Pesola, Matejka Rebolj, Simon Leeson, Louise Dunk, Louise Pickford, Ardiana Gjini, Peter Sasieni |
| 4. Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing | Attendance at early recall and colposcopy is crucial to attaining the benefits of primary high-risk human papillomavirus (HR-HPV)-based screening. Within the English HPV pilot, we analysed deprivation- and age-related patterns of attendance at colposcopy and 12- and 24-month early recall of HR-HPV positive women screened in 2013 to 2015. | International Journal of Cancer
Leonardo I Green, Christopher S Mathews, Jo Waller, Henry Kitchener, Matejka Rebolj, HPV Pilot Steering Committee |
| 5. Maximising the acceptability of extended time intervals between screens in the NHS Cervical Screening Programme: An online experimental study | The NHS Cervical Screening Programme plans to increase the screening interval from 3 to 5 years for women aged 25-49 who test negative for human papillomavirus (HPV). This exploratory cross-sectional online survey tested the impact of different levels of information about the proposed change on acceptability of a longer interval. | Journal of Medical Screening
Emily Hill, Martin Nemec, Laura Marlow, Susan Mary Sherman, Jo Waller |
| 6. Exploring reasons for variations in anxiety after testing positive for human papillomavirus with normal cytology: a comparative qualitative study | This study aimed to explore reasons for variations in anxiety in women testing positive for human papillomavirus (HPV) with normal cytology at routine HPV primary cervical cancer screening. | Psycho-Oncology
Emily McBride, Laura A. V. Marlow, Kirsty F. Bennett, Selma Stearns, Jo Waller |
| 7. ‘Immunity Passports’ for SARS-CoV-2: an online experimental study of the impact of antibody test terminology on perceived risk and behaviour | This study aimed to assess the impact of describing an antibody positive test result using the terms Immunity and Passport
or Certificate, alone or in combination, on perceived risk of becoming infected with SARS-CoV-2 and protective behaviours. |
BMJ Open
Jo Waller, G James Rubin, Henry W W Potts, Abigail L Mottershaw, Theresa M Marteau |
| 8. Lung Screen Uptake Trial (LSUT): Randomized Controlled Clinical Trial Testing Targeted Invitation Materials. | This study aimed to compare the effect of a targeted, low-burden, and stepped invitation strategy versus control on uptake of hospital-based Lung Health Check appointments offering LDCT screening. | American Journal of Respiratory and Critical Care Medicine
Samantha L. Quaife, Mamta Ruparel, Jennifer L. Dickson….. Stephen W. Duffy, Jane Wardle, Jo Waller, and Samuel M. Janes |
| 9. Decision-making about HPV vaccination in parents of boys and girls: A population-based survey in England and Wales | School-based HPV vaccination in the UK will soon be extended to boys. Based on other countries’ experience, uptake may initially be lower in boys than girls. We assessed HPV vaccine attitudes and decision-making in parents of boys and girls, to explore sex differences and inform public health messages. | Vaccine
Jo Waller, Alice Forster, Mairead Ryan, Rebecca Richards, Helen Bedford, and Laura Marlow |
| 10. Attitudes towards risk-stratified breast cancer screening among women in England: A cross-sectional survey | Risk stratification may improve the benefit/harm ratio of breast screening. Research on acceptability among potential invitees is necessary to guide implementation. We assessed women’s attitudes towards and willingness to undergo risk assessment and stratified screening. | Journal of Medical Screening
Alex Ghanouni, Saskia C Sanderson, Nora Pashayan, Cristina Renzi, Christian von Wagner, Jo Waller |
| 11. Lectins in Cervical Screening | Lectins discriminate between dysplasia and normal tissue in several precancerous conditions. We explored whether lectins could be developed for cervical screening via visual inspection. | Cancers (Basel)
Anita Lim, Neves AA, Lam Shang Leen S, Lao-Sirieix P, Bird-Lieberman E, Singh N, Sheaff M, Hollingworth T, Brindle K, Peter Sasieni. |
| 12. Technological advances: Have they improved standards? Review of outcomes from the Welsh cervical screening programme | Introduction of new technologies into cervical screening programmes has allowed more efficient programmes with less resources. The aim was to present an overview of screening technologies introduced into the Cervical Screening Wales programme and their evolution over time. | Journal of Medical Screening
Alejandra Castanon |
| 13. Evidence of HPV vaccination efficacy comes from more than clinical trials | This editorial discusses the non-trial research evidence that enables most scientists to conclude that HPV vaccination will prevent most cervical cancers. | Vaccine
Peter Sasieni & Alejandra Castanon |
| 14. Survival from Cervical Cancer Diagnosed Aged 20-29 Years by Age at First Invitation to Screening in England: Population-Based Study | This study estimated 8-year overall survival (OS) from cervical cancer in women under age 30y by International Federation of Gynecology and Obstetrics (FIGO) stage and age at first screening invitation. | Cancers (Basel)
Alejandra Castanon, Daniela Tataru, Peter Sasieni |
| 15. Impact of changes to cervical screening guidelines on age and interval at which women are tested: Population-based study | English cervical screening programme guidelines changed between 2009 and 2012. We explore the impact on the age and intervals at which women receive a cytology test. | Journal of Medical Screening
Alejandra Castanon, Shama Sheikh, Philippa Pearmain, Peter Sasieni |
| 16. Cost-effectiveness of e-cigarettes compared with nicotine replacement therapy in stop smoking services in England (TEC study): a randomized controlled trial | This study aimed to evaluate the cost-effectiveness of e-cigarettes as a smoking cessation aid used in routine stop smoking services in England. | Addiction
Jinshuo Li, Peter Hajek, Francesca Pesola, Qi Wu, Anna Phillips-Waller, ….., Peter Sasieni 3, …, Steve Parrott. |
| 17. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial | The appropriate age range for breast cancer screening remains a matter of debate. We aimed to estimate the effect of mammographic screening at ages 40-48 years on breast cancer mortality. | Lancet Oncology
Stephen Duffy , Daniel Vulkan , Howard Cuckle, Dharmishta Parmar, Shama Sheikh, Robert Smith, ….., Peter Sasieni , …. Sue Moss |
| 18. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial | The aim of this study was to investigate whether offering this test to patients on medication for gastro-oesophageal reflux would increase the detection of Barrett’s oesophagus compared with standard management. | Lancet
Rebecca C Fitzgerald, Massimiliano di Pietro, Maria O’Donovan, Roberta Maroni, Beth Muldrew , Irene Debiram-Beecham, Marcel Gehrung , Judith Offman Monika Tripathi , Samuel G Smith, Benoit Aigret, …. Peter Sasieni |
| 19. Impact of screening on cervical cancer incidence: A population-based case-control study in the United States | We assessed the effectiveness of cervical screening in New Mexico using a case–control study design. We addressed three questions which together provide insights into the effectiveness of screening on a state‐wide basis. | International Journal of Cancer
Rebecca Landy, Peter D Sasieni , Christopher Mathews , ……, Jack Cuzick, Cosette M Wheeler, New Mexico HPV Pap Registry Steering Committee |
| 20. A state-wide population-based evaluation of cervical cancers arising during opportunistic screening in the United States | Despite widespread cervical screening, an estimated 13,800 women will be diagnosed with cervical cancer in the United States in 2020. To inform improvements, the screening histories of women diagnosed with cervical cancer in New Mexico were assessed. | Gynecol Oncol
Rebecca Landy , Christopher Mathews , Michael Robertson , Charles L Wiggins , Yolanda J McDonald, Daniel W Goldberg, Isabel C Scarinci, Jack Cuzick , Peter D Sasieni, Cosette M Wheeler
|
| 21. Cancer Screening, Surrogates of Survival, and the Soma | Screening leads to meaningful reductions in deaths from cancers. However, reductions in all-cause mortality (ACM) are harder to demonstrate. Failure to demonstrate ACM benefit should not diminish advances in cancer screening. We consider how co-morbidities related to an aging and damaged soma can hinder achievement of ACM benefit. | Cancer Cell
James DeGregori, Paul Pharoah, Peter Sasieni, Charles Swanton |
| 22. Weekly COVID-19 testing with household quarantine and contact tracing is feasible and would probably end the epidemic | The combination of regular testing with strict household quarantine has remarkable power to reduce transmission to the community from other household members as well as providing earlier diagnosis and facilitating rapid contact tracing. | R Soc Open Sci
Julian Peto, James Carpenter, George Davey Smith, Stephen Duffy, Richard Houlston, David J Hunter, Klim McPherson, Neil Pearce, Paul Romer, Peter Sasieni, Clare Turnbull |
| 23. Worldwide Review and Meta-Analysis of Cohort Studies Measuring the Effect of Mammography Screening Programmes on Incidence-Based Breast Cancer Mortality | We carried out a systematic review of incidence-based mortality studies of breast cancer screening programmes, and a meta-analysis of the estimated effects of both invitation to screening and attendance at screening, with adjustment for self-selection bias, on incidence-based mortality from breast cancer. The results of the meta-analysis showed a significant 22% reduction in breast cancer mortality with invitation to screening, with a relative risk of 0.78 and a significant 33% reduction with actual attendance at screening. | Cancers
Amanda Dibden, Judith Offman, Stephen W Duffy, Rhian Gabe |
| 24. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers | To report the utility of PSA (prostate-specific-antigen) screening, prostate cancer incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. | European Urology
Elizabeth C Page, Elizabeth K Bancroft, Mark N Brook…. Judith Offman, Zsofia Kote-Jarai, Andrew Vickers, Hans Lilja, Rosalind A Eeles
|
| 25. Population-level impact of human papillomavirus vaccination | In this editorial we argue that the effect of vaccination in a population depends not only on the vaccine but also on the proportion of the population vaccinated. Hence, we would not expect the relative risk observed in different populations to be alike unless they had similar vaccine coverage. It is not enough to consider the uptake in the target population, as the coverage of the population studied also needs to be taken into account. | Lancet
Peter Sasieni & Jack Cuzick |
The views expressed are those of the author. Posting of the blog does not signify that the Cancer Prevention Group endorse those views or opinions.
Share this Page
Leave a Reply